AstraZeneca

The OD’s role with new diabetes drugsIt is important for eyecare providers to be familiar with these new drugs and findings. We often see patients with diabetes, metabolic syndrome, and high CV risk, and we are in a position to help counsel our patients about new treatments—and even suggest that appropriate patients have conversations with their primary-care physicians, endocrinologists and cardiologists.
FDA okays unique injectable for type 2 diabeticsFDA approved a new once-weekly, single-dose autoinjector device to improve glycemic control in adults with type 2 diabetes.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentOther pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Fasting regimens may be key in treating type 2 diabetesFasting regimens have gained popularity as a technique for reducing weight and obesity. This strategy may improve insulin sensitivity in patients with insulin resistance and diabetes.
Effects of concurrent use of topical, oral beta blockersRecently, I received a progress note from a glaucoma surgeon concerning a patient whom he and I share. The patient is a 58-year-old African-American female with a longstanding history of primary open-angle glaucoma.
Big savings expected with new generic antipsychoticFDA tentatively approved the abbreviated new drug application (ANDA) for generic quetiapine fumarate extended-release tablets (brand Seroquel XR, AstraZeneca) to treat schizophrenia and manic/mixed episodes associated with bipolar disorder.
New kidney warning on popular diabetes drugsSoon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet, Janssen Biotech), the agency strengthened the existing warning about the risk of acute kidney injury with Invokana and Invokamet, as well as dapagliflozin (Farxiga and Xigduo XR, AstraZeneca).
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
FDA expands use for breast cancer drugFDA has approved expanded indication for the use of fulvestrant (Faslodex, AstraZeneca) in combination with another therapy in the treatment of metastatic breast cancer.
Leading heartburn drugs linked to dementiaSeniors who regularly took leading heartburn drugs such as Nexium, Prilosec and Prevacid (Takeda Pharmaceuticals) were 44% more likely to end up with dementia, according to a new study.